REGULATORY
MHLW to Issue Development Requests for New Uses of Rituxan, Truvada, and More
A council of the Ministry of Health, Labor and Welfare (MHLW) on August 30 agreed that high medical needs exist for label expansions of five medicines, including Rituxan (rituximab) for a new pediatric indication and Truvada (emtricitabine + tenofovir disoproxil…
To read the full story
Related Article
REGULATORY
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





